Article ; Online: A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications.
2020 Volume 34, Issue 6, Page(s) 7265–7269
Abstract: As of April 20, 2020, over time, the COVID-19 pandemic has resulted in 157 970 deaths out of 2 319 066 confirmed cases, at a Case Fatality Rate of ~6.8%. With the pandemic rapidly spreading, and health delivery systems being overwhelmed, it is imperative ...
Abstract | As of April 20, 2020, over time, the COVID-19 pandemic has resulted in 157 970 deaths out of 2 319 066 confirmed cases, at a Case Fatality Rate of ~6.8%. With the pandemic rapidly spreading, and health delivery systems being overwhelmed, it is imperative that safe and effective pharmacotherapeutic strategies are rapidly explored to improve survival. In this paper, we use established and emerging evidence to propose a testable hypothesis that, a vicious positive feedback loop of des-Arg(9)-bradykinin- and bradykinin-mediated inflammation → injury → inflammation, likely precipitates life threatening respiratory complications in COVID-19. Through our hypothesis, we make the prediction that the FDA-approved molecule, icatibant, might be able to interrupt this feedback loop and, thereby, improve the clinical outcomes. This hypothesis could lead to basic, translational, and clinical studies aimed at reducing COVID-19 morbidity and mortality. |
---|---|
MeSH term(s) | Betacoronavirus ; Bradykinin/analogs & derivatives ; Bradykinin/pharmacology ; Bradykinin/physiology ; Bradykinin/therapeutic use ; Bradykinin B2 Receptor Antagonists/pharmacology ; Bradykinin B2 Receptor Antagonists/therapeutic use ; Compassionate Use Trials ; Coronavirus Infections/complications ; Coronavirus Infections/drug therapy ; Coronavirus Infections/physiopathology ; Dyspnea/etiology ; Dyspnea/physiopathology ; Feedback, Physiological/drug effects ; Humans ; Inflammation ; Models, Biological ; Off-Label Use ; Pandemics ; Peptidyl-Dipeptidase A/physiology ; Pneumonia, Viral/complications ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/physiopathology ; Receptors, Bradykinin/drug effects ; Receptors, Bradykinin/physiology ; Receptors, Virus/physiology |
Chemical Substances | Bradykinin B2 Receptor Antagonists ; Receptors, Bradykinin ; Receptors, Virus ; bradykinin, des-Arg(9)- (15958-92-6) ; icatibant (7PG89G35Q7) ; Peptidyl-Dipeptidase A (EC 3.4.15.1) ; angiotensin converting enzyme 2 (EC 3.4.17.-) ; Bradykinin (S8TIM42R2W) |
Keywords | covid19 |
Language | English |
Publishing date | 2020-05-02 |
Publishing country | United States |
Document type | Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 639186-2 |
ISSN | 1530-6860 ; 0892-6638 |
ISSN (online) | 1530-6860 |
ISSN | 0892-6638 |
DOI | 10.1096/fj.202000967 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 2266: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MO 296: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.